DDInter1397 DDInter484
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Paroxetine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Paroxetine {u} (Compound) upregulates {v} (Gene) DDR1
DDR1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Paroxetine {u} (Compound) downregulates {v} (Gene) B4GAT1
B4GAT1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Paroxetine {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Paroxetine {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Paroxetine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Paroxetine {u} (Compound) upregulates {v} (Gene) DDR1
DDR1 {u} (Gene) covaries with {v} (Gene) TESK1
TESK1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Paroxetine {u} (Compound) upregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is regulated by {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Paroxetine {u} (Compound) downregulates {v} (Gene) B4GAT1
B4GAT1 {u} (Gene) is regulated by {v} (Gene) FYN
FYN {u} (Gene) is bound by {v} (Compound) Dasatinib
Paroxetine {u} (Compound) upregulates {v} (Gene) PRKCQ
PRKCQ {u} (Gene) is downregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Paroxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Paroxetine (Compound) upregulates DDR1 (Gene) and DDR1 (Gene) is upregulated by Dasatinib (Compound)
Paroxetine (Compound) downregulates B4GAT1 (Gene) and B4GAT1 (Gene) is upregulated by Dasatinib (Compound)
Paroxetine (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Dasatinib (Compound)
Paroxetine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Paroxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound)
Paroxetine (Compound) upregulates DDR1 (Gene) and DDR1 (Gene) covaries with TESK1 (Gene) and TESK1 (Gene) is bound by Dasatinib (Compound)
Paroxetine (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is regulated by ABL1 (Gene) and ABL1 (Gene) is bound by Dasatinib (Compound)
Paroxetine (Compound) downregulates B4GAT1 (Gene) and B4GAT1 (Gene) is regulated by FYN (Gene) and FYN (Gene) is bound by Dasatinib (Compound)
Paroxetine (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is downregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound)